NeuBase Therapeutics soars as Symetryx acquires 20% of co's shares

NeuBase Therapeutics

06/09/2023 17:46

** Shares of NeuBase Therapeutics  NBSE.O , a
preclinical-stage biotech company, more than double to over
two-month high of $2.54    
    ** Privately-held Symetryx Corp says it has acquired 20% of
the issued and outstanding common stock in NeuBase   
    ** Symetryx says it bought these shares on open market and
is now urging NBSE Board to issue a special $1/shr dividend 
     ** Symetryx says NBSE's cash position of $14.7 mln, as of
June 30, 2023, makes it a "very attractive" merger candidate
    ** NBSE is currently undergoing a strategic review of the
company's operations
    ** Including session's gain, stock down ~25.6% YTD 

 (Reporting by Mariam Sunny in Bengaluru)
 ((Mariam.ESunny@thomsonreuters.com;))